[1]   贾俊. 红花注射抗血栓药效物质基础初步研究[D]. 太原: 山西大学, 2010.

[2]   Martine Gilard, Paul Barragan, Arif A L Noryani. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial [J].J Am coll cardiol, 2015, 65(8):777-786.

[3]   周铭. 血小板聚集功能的检测——光谱学及软 X 线成像研究[D].合肥：安徽医科大学, 2016.

[4]   王晓锋, 陈乃宏, 王文. 抗血小板聚集药物的机制研究进展[J]. 中国康复理论与实践, 2010, 16(10): 954-957.

[5]   Shaturny? V I, Shakhidzhanov SS, Sveshnikova AN, Panteleev MA. Activators, receptors and signal transduction pathways of blood platelets [J]. Biomed Khim. 2014, 60(2):182-200

[6]   Liu Yang-yang, Hu Meng-jiao. Luo Dong-jiao, et al. Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase[J]. Arterioscler Thromb Vasc Biol, 2018, 38(3): e26-e27.

[7]   Zoubir Djerada, Catherine Feliu, Vincent Richard. Current knowledge on the role of P2Y receptors in cardioprotection against ischemia-reperfusion [J]. Pharmacol Res, 2017, 118: 5-18.

[8] 陆四, 孟照辉. 血小板膜蛋白受体信号转导通路的研究进展[J]. 医学综述, 2014, 20(21): 3851-3854.

[9] Atkinson L, Yusuf1 M.Z, Aburima A, et al. Reversal of stress fibre formation by Nitric Oxide mediated RhoA inhibition leads to reduction in the height of preformed thrombi [J]. Sci Rep, 2018, 8(1):3032

[10] Yusuf M Z, Raslan Z, Atkinson L, et al. Prostacyclin reverses platelet stress fibre formation causing platelet aggregate instability [J]. Scientific, 2017, 7(1): 5582

[11] Wu Chin-chung, Teng Che-ming. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation [J]. Eur J Pharmacol, 2006, 546(1-3): 142-47.

[12] 余果宇，张勇，江萍. 蛋白酶激活受体[J]. 生命的化学, 2011, 31(03): 425-428.

[13] Beatrice Hechler, Christian Gachet. P2 receptors and platelet function［J］. Purinergic Signal, 2011, 7(3): 293-303

[14] Pia R M Siljander, Imke C A Munnix, Peter A Smethurst, et al. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood[J]. Blood, 2004, 103(4): 1333-1341.

[15] Jane F Arthur, Elizabeth Gardiner, Maria Matzaris, et al. Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets[J]. Thromb Haemost, 2005, 93(4): 716-23.

[16] 李雪晴, 耿婷. 血小板活化因子(PAF) 受体拮抗剂的研究进展[J].中国中药杂志, 2018, 24(04): 1392-1403

[17] Federico Iovino, Matthijs C Brouwer, Diederik van de Beek, et al. Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease [J]. Cell Microbiol, 2013, 15(6): 870-881

[18] Omair Yousuf, Deepak L Bhatt. The evolution of antiplatelet therapy in cardiovascular disease [J]. Nat Rev Cardiol, 2011, 8(10): 547-59.

[19]   Gu X, Fu X, Wang Y, et al. Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrel [J]. Am J Cardiovasc Dis, 2017, 7(1):1-8

[20]    董慧宇, 陈献华. P2Y12受体拮抗剂类抗血小板药物的研究新进展[J].中国新药杂志，2017, 26(12):1406-1411

[21] Beatrice Hechler, Christelle Nonne, Eun Joo Roh, et al. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice[J]. J Pharmacol Exp Ther, 2006, 316(2): 556-63.

[22] Maree A O, Cox D, Fitzgerald D J. Drug insight: aspirin resistance-fact or fashion? [J]. Nat Clin Pract Cardiovasc Med, 2007, 4(3): E1

[23] Xu Li-na, Yu Wen-gui, Tian Jin-ying, et al. Effect of sodium ferulate on arachidonic acid metabolism[J]. Acta Pharm Sin, 1990, 25(6) : 412-416.

[24] Jantan I, Raweh S M, Sirat H M, et al. Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation[J].  Phytomedicine, 2008, 15(4): 306-309

[25] Marilena Crescente, Gisela Jessen, Stefania Momi, et al. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cycloox-ygenase-1 level. Functional and modelling studies[J]. Thromb Haemost, 2009, 102(2): 336-346.

[26] 张林山. PAR-1受体拮抗剂E5555类似物的研究[D]. 青岛: 青岛科技大学，2012.

[27] Shinya Goto, Testu Yamaguchi, Yasuo Ikeda, et al. Safety and exploratory efficacy of the novel thrombin receptor(PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome [J]. J Atheroscler. Thromb, 2010, 17 (2): 156-164.

[28] Jennifer Vergara-Jimenez, Pierluigi Tricoci. Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention [J]. Vasc Health Risk Manag, 2010, 6: 39-45.

[29] 陈俞宏, 李孝成. 低分子肝素结合替罗非班治疗老年急性下肢深静脉血栓对 PAC-1、P 选择素的影响[J]. 中国现代医学杂志, 2018, 28(03): 64-68

[30]  高稳, 李健. EＲK5对体外血小板活化及在体血栓的影响[J].中国病理生理杂志, 2017, 33(11): 1958-1963

[31] Li Wei, Yue Hong. Thymidine phosphorylase: A potential new target for treating cardiovascular disease [J]. Science Direc, 2018, 28(3): 157-171

[32] Diana A Gorog, Zahi A Fayad, Valentin Fuster. Arterial thrombus stability: does it matter and can we detect it? [J]. J Am Coll Cardiol, 2017, 70(16): 2036–2047.